American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities

American Peptide Company has announced the formation of a new research and development group. Created to offer technology capabilities to a growing roster of global pharmaceutical and biotech customers, the R&D group will be based at the company’s Sunnyvale, California facility and will be tasked with the development of new products and services.

Peptide drugs are increasing in complexity, now requiring challenging modifications, incorporating unnatural amino acids, and being linked to carrier molecules to enhance drug delivery efficacy.

Designed for indications to treat ailments such as diabetes, HIV, neurological disorders like Alzheimer’s disease, cardiovascular diseases, and cancer, peptides have tremendous therapeutic potential, but can be difficult to synthesize to the high quality necessary for research and commercial production. American Peptide Company has instituted the R&D group to help meet this industry need and provide peptide solutions to the drug development community.

“The new R&D group will better enable American Peptide Company to meet the complex and evolving needs of our global customer base,” says Takahiro Ogata, President & COO of American Peptide Company. “This initiative fits well with our broader company mission to provide Total Peptide Management solutions to drug researchers and developers pioneering solutions for improving human life. The R&D group and the technological capabilities they offer will ultimately help our customers more effectively drive bioactive peptides identified as potential drug targets through the discovery and development phase.”